August 1, 2011 |
May 25, 2012 |
August 2011 |
December 2012 (final data collection date for primary outcome measure) |
|
Same as current |
Complete list of historical versions of study NCT01407497 on ClinicalTrials.gov Archive Site |
|
|
|
|
|
Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine |
A Phase I Trial to Assess Safety and Immunogenicity of i.d. DNA Priming and i.m. MVA Boosting in Healthy Volunteers in Mozambique and to Develop Further HIV Vaccine Trial Capacity Building in Mozambique |
While antiretroviral drugs have shown great promise in reducing HIV replication and thus in reducing HIV/AIDS associated morbi-mortality and HIV transmission, the cost is substantial and side effects are a potentially limiting factor. Development of an effective safe-affordable vaccine is likely to be the best way to stop further virus spread. The study aims to determine safety and immunogenicity of the DNA-vaccine at a dose of 600µg and 1200µg delivered id in combination with MVA-CMDR boost im. |
|
Interventional |
Phase 1 |
Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
HIV Infections |
- Biological: DNA HIVIS and MVA-CMDR
600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12; 108 pfu i.m. MVA boosting at weeks 24 and 36
- Biological: DNA HIVIS and MVA-CMDR
1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 ; 108 pfu i.m. MVA boosting at weeks 24 and 36
- Biological: Saline solution
2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
- Biological: Saline solution
2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
|
- Active Comparator: IA
600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 108 pfu i.m. MVA boosting at weeks 24 and 36
Intervention: Biological: DNA HIVIS and MVA-CMDR
- Placebo Comparator: IB
2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 saline solution i.m at weeks 24 and 36
Intervention: Biological: Saline solution
- Active Comparator: IIA
1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12;108 pfu i.m. MVA boosting at weeks 24 and 36
Intervention: Biological: DNA HIVIS and MVA-CMDR
- Placebo Comparator: IIB
2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
Intervention: Biological: Saline solution
|
|
|
Active, not recruiting |
24 |
|
December 2012 (final data collection date for primary outcome measure) |
Inclusion Criteria:
- Age: 18 to 26 years
- Willing to undergo HIV (Human Immunodeficiency Virus) counseling and testing
- Have a negative antigen/antibody or antibody ELISA for HIV infection
- Able to give informed consent
- Satisfactory completion of an assessment of understanding prior to enrolment defined as 89% correct answers after three opportunities to take the test
- Basic abilities to read and write
- Resident in Maputo, and willing to remain so for the duration of the study
At low risk of HIV infection, defined as the absence of an identifiable risk factor/ behavior (their presence is therefore an exclusion criteria):
- sexual partner with HIV
- sexual partner with unknown HIV serostatus who is also unwilling to use protective condoms consistently in all sexual relations
- sexual partner is known to be at high risk for HIV
- more than one sexual partner in the last 6 months
- history of being an alcoholic [as medically defined or more than 35 units /week]
- history of Sexually Transmitted Infection (STI) within past 6 months
- Verbal assurances that adequate birth control methods are used not to conceive/father a child during the study and up to 3 months after the last vaccine injection.
- Women shall have a negative urine pregnancy test
- Be willing to practice safe sex for the duration of the study to avoid sexually transmitted infections including HIV
- Good health as determined by medical history, physical examination, clinical judgment and by key laboratory parameters as judged by the study physician.
Laboratory criteria:
- Hemoglobin >10.5g/dl
- White blood cell count <13,000/mm3
- Neutrophils >1,300/mm3
- Lymphocytes >1.000/ mm3
- Platelets >120,000/ mm3
- Random Blood Glucose < 6.44 mmol/L; if elevated, then a Fasting Blood Glucose < 6.11mmol/L (according to DAIDS Table for Lab Criteria)
- Bilirubin <1.25 x uln
- Alanine transaminase (ALT) <1.25 x uln
- Urine dipstick for protein and blood: negative or trace. (If either is ¿ 1+, complete urinalysis (UA) will be performed.
Exclusion Criteria:
- At risk of HIV infection as mentioned above in the inclusion criteria
- Active tuberculosis or other systemic infectious process elicited by review of systems, physical examination and laboratory detection
- A history of immunodeficiency, chronic illness requiring continuous or frequent medical intervention
- Autoimmune disease by history and physical examination
- Hives or recurrent hives and severe eczema
- A history of psychiatric, medical (including traditional medicine) and/or substance abuse problems during the past 6 months that the investigator believes would adversely affect the volunteer's ability to participate in the trial
- History of epilepsy, or currently taking anti-epileptics
- Received blood or blood products or immunoglobulins in the past 3 months
- Receiving immunosuppressive therapy such as systemic corticosteroids or cancer chemotherapy
- Use of experimental therapeutic agents within 30 days of study entry
- Reception of any live, attenuated vaccine within 60 days of study entry.
- Abnormality in Electrocardiogram (ECG) that could indicate risk or make interpretation of vaccine effects difficult according to the study operating procedures
- Previously received an HIV vaccine candidate
History of severe local or general reaction to vaccination defined as:
- Local: Extensive, indurate redness and swelling involving most of the major circumference of the arm, not resolving within 72 hours
- General: Fever >= 39.5 0C within 48 hours; anaphylaxis; bronchospasm; laryngeal edema; collapse; convulsions or encephalopathy within 72 hours
- Being a lactating mother
- Study site employees who are involved in the protocol and may have direct access to the immunogenicity results
- Unlikely to comply with protocol as judged by the principal investigator or his designate.
|
Both |
18 Years to 26 Years |
Yes |
Contact information is only displayed when the study is recruiting subjects |
Mozambique |
|
NCT01407497 |
TAMOVAC-01-MZ |
Yes |
Instituto Nacional de Saúde, Mozambique |
Instituto Nacional de Saúde, Mozambique |
- Swedish Institute for Communicable Disease Control, Sweden
- European and Developing Countries Clinical Trials Partnership (EDCTP)
|
Principal Investigator: |
Ilesh Jani, PhD |
Instituto Nacional de Saúde |
|
Principal Investigator: |
Nafissa Osman, MD, PhD |
Hospital Central de Maputo |
|
|
Instituto Nacional de Saúde, Mozambique |
August 2011 |